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Introduction
Alpha-fetoprotein (AFP) and ultrasonography are 2
important noninvasive modalities for early detection
of hepatocellular carcinoma (HCC).1 Cirrhotic nodules
are found frequently with increasing use of abdominal
ultrasound.2 AFP elevation is not uncommon in such
cases because liver inflammation is generally coexistent
in the cirrhotic liver.3,4 AFP-L3 is a fucosylated species
of AFP that is the product of α1-6 fucosyltransferase
in the presence of GDP fucose.5–7 This enzyme activity
was higher in HCC tissues than in the surrounding non-
tumor tissue.8 Therefore, AFP-L3 is considered more
specific than AFP in diagnosis of HCC.9–11 It has been
used for early detection of HCC9–18 and evaluation for
recurrent tumor after treatment.19–25
Transient elevation of AFP in patients with chronic
liver disease is associated with hepatocyte regeneration
in responding to liver necroinflammation.26,27 Persistent
elevation of AFP is found in some of these patients.
Detection of HCC by ultrasound in patients with ele-
vation of AFP may be difficult when cirrhotic nodule
is present. We evaluated AFP-L3 in patients with per-
sistent elevation of AFP to understand whether it may
be of help in the diagnosis of HCC.
Methods
Patients
Patients who visited Chang Gung Memorial Hospital
with chronic liver disease and elevated AFP by ra-
dioimmunoassay were reviewed from January 2002
to December 2002. Patients with persistent elevation
of AFP > 50 ng/mL for longer than 6 months were
included as study group B. Patients with single elevation
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of AFP >900ng/mL and transaminase level >200U/L
were included as liver regeneration control (group A).
Patients with HCC and AFP > 50 ng/mL were ran-
domly selected as the disease control group (group C).
We selected patients in group B and C with total AFP
> 50 ng/mL because it is the lowest limit for detection
of AFP-L3. Total AFP > 900 ng/mL is relatively rare
in patients with chronic hepatitis and generally asso-
ciated with severe liver damage. Therefore, total AFP
> 900 ng/mL was used as a lower enrolment limit for
patients in group A. Patients who were diagnosed with
acute hepatitis as evidenced by positive anti-HBc IgM
or anti-HAV IgM were excluded from this study.
All of the patients received liver biochemistry,
AFP, viral markers and abdominal ultrasound studies.
Serum AFP was measured by radioimmunometric
assay (ELSA2-AFP; CIS Bio-International, Cedex,
France). Hepatitis B surface antigen (HBsAg) and anti-
hepatitis C virus antibody (anti-HCV) were measured
by enzyme-linked immunosorbent assay (Abbott Ausria-
II and Abbott HCV-ELISA III; Abbott Laboratories,
Abbott Park, IL, USA). Residual sera were frozen in
–20°C until AFP-L3 study. This study was approved
by the ethics committee of Chang Gung Memorial
Hospital.
Assay of serum AFP-L3
AFP-L3 studies were done by lectin-affinity electro-
phoresis coupled with antibody-affinity blotting (AFP
Differential Kit, kindly supplied by Wako Chemicals,
Osaka, Japan). Sera with AFP > 200 ng/mL were di-
luted to approximately 100 ng/mL using normal hu-
man serum provided in the kids. Each prepared sample
(4 µL) was applied to wells on the lectin-agarose gel.
Before electrophoresis, the electrophoretic chamber and
electrode buffer were cooled to below 15°C. Electro-
phoresis was carried out at a constant voltage of 200V ±
10% for 50 minutes. After electrophoresis, separated
AFP bands were blotted on nitrocellulose membranes
pre-coated with affinity-purified equine antibodies to
human AFP at room temperature for 30 minutes at
37°C with 4 mL of rabbit AFP antibody solution. Then
the membrane was exposed to affinity-purified goat rab-
bit immunoglobulin G antibodies labeled with horse-
radish peroxidase for 30 minutes at 37°C. For coloring
reaction, 10 mL of the enzyme-substrate solution was
added. The system was kept at room temperature for
30 minutes and then gently washed and dried after color
developed. AFP bands were then measured by scanning
with a Fluor-S Multi-Imager (Bio-Rad Laboratories,
Hercules, CA, USA). The bands appearing after electro-
phoresis are shown in Figure 1. The results of AFP-L3
are expressed as percentage of AFP-L3 to total AFP.
Subsequent clinical evaluation
Liver biochemistry, AFP and abdominal ultrasound
studies were done prospectively at 3- to 6-month
intervals after enrolment. Patients who failed to fol-
low the study protocol were actively reminded by
telephone.
Diagnosis of liver cirrhosis was mainly based on ultra-
sound scoring system,28 varices detected by endoscopy
or histology study.
Computed tomography (CT), magnetic resonance
imaging (MRI), angiography, cytology and/or histology
were done when HCC was suspected.
Diagnosis of HCC was made mainly by histology or
cytology studies. Long-term evaluation of tumor pro-
gression by imaging and AFP studies were used for those
patients who could not undergo histology or cytology
studies.
Statistical analysis
Data are expressed as mean ± standard deviation. Statis-
tical significance was determined by using the Student’s
t test for continuous variables and the χ2 test for the
difference in proportions between groups. Scheffe’s
method was used for multiple comparisons. Receiver
operating characteristic curves were created to estab-
lish the optimal cutoff values. A life table was used to
compare the HCC-free survival between patients with
AFP-L3 greater or lower than 15%. Statistical analysis
was performed using SPSS version 11.5.0 (SPSS Inc.,
Chicago, IL, USA) for Windows. A p value less than
0.05 was considered statistically significant.
Results
The clinical characteristics of the 17 patients in group A,
39 patients in group B and 41 patients in group C 
are listed in Table 1. Patients in group A were the
youngest, with the highest alanine aminotransferase
level, highest HBsAg prevalence and lowest rate of liver
cirrhosis among the 3 groups. The clinical character-
istics of the patients and diagnostic modalities of HCC
are listed in Table 2. The mean AFP-L3 ratio was
highest in group C, followed by group B and finally
group A.
HCC and AFP-L3 cutoff value
HCC was detected in 1 patient in group B 20 months
after enrolment. His AFP-L3 was strongly positive at
the time of study (Figure 1). Based on this finding, 
we evaluated the value of AFP-L3 in prediction of
HCC within 2 years after enrolment. One patient in
group A and 13 patients in group B developed HCC
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within 2 years after AFP-L3 study. Additional HCC
was detected in 2 patients in group A and 1 patient in
group B during the third year.
In the total number of study patients, both sensi-
tivity and specificity of AFP-L3 for prediction of HCC
in the next 2 years were 71% if the cutoff value was
15% (Figure 2). The sensitivity decreased to 66.5%
while the specificity increased to 82% if the cutoff ratio
was 17.5%.
Similar results were found when group A was ex-
cluded. The sensitivity was 70% and specificity was 73%
when the cutoff value of AFP-L3 ratio was 15%. The
sensitivity decreased to 66.7% while the specificity in-
creased to 88.5% if the cutoff ratio was 17.5%. When
only group B was examined, the sensitivity was 53.8%
and specificity was 72%.
When the cutoff value of AFP-L3 was 15%, the HCC
prediction rate was 70.9% for the total number of study
patients (p = 0.000). For each group of patients, the
HCC prediction rate was 100% in group A, 53.8% in
group B (p = 0.098) and 75.6% in group C (Table 3).
HCC-free survival analysis
We divided all the patients in group A and B into 
2 groups according to AFP-L3 level at enrolment. By
life table analysis, those patients with AFP-L3 ≥ 15%
showed a lower HCC-free survival than those patients
with AFP-L3 < 15% (p = 0.072; Figure 3).
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Figure 1. (A) A patient with persistent elevation of α-fetoprotein (AFP) without imaging-detectable hepatocellular carcinoma (HCC). An
HBsAg carrier presented with persistently elevated total AFP level. Repeated ultrasound studies and a computed tomography (CT) scan
were unable to locate the nodule. Three years later, a 2.5-cm nodule was found in the caudate lobe by imaging and histology studies.
AFP dropped to normal after transhepatic arterial chemoembolization (TACE) and surgical excision. (B) A strong AFP-L3 (AFP-L3 to total
AFP ratio, 70%; white arrow) was identified by lectin-affinity electrophoresis 20 months before the diagnosis of HCC.
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Relation of tumor size with AFP-L3
AFP-L3 ≥ 15% was found in 57.1% of patients with
HCC in group B when their tumors were unde-
tectable. For tumors < 2 cm, 60% of them had AFP-
L3 ≥ 15%; it was 81.3% for tumor size 2–5 cm and
90% for tumor > 5 cm. A significant correlation of
AFP-L3 with tumor size was found (p = 0.037, χ2 for
trend).
Sequential AFP-L3 studies
Eleven patients in group B received a second AFP-L3
study when HCC was found. Six of them had AFP-L3
Table 1. Demographic characteristics of study patients
Group A (transient high Group B (persistent 
Group C (HCC) Multiple comparison
AFP elevation) AFP elevation)
Total case no. 17 39 41
AFP at study > 900 ng/mL > 50 ng/mL > 50 ng/mL
M:F 15:2 22:17 30:11 A ≠ B = C
Age, yr 45.5 ± 15.1 56.7 ± 13.0 57.5 ± 13.8 A ≠ B = C
Duration of AFP elevation, – 3.6 ± 3.2 (0.5–15) –
yr (range)
Viral markers
HBsAg(+) 15 11 19
Anti-HCV(+) 1 19 16
Dual infection 1 8 3
NBNC 0 1 3
AFP (ng/mL) 1,254.4 ± 354.4 151.4 ± 170.2 2,802.2 ± 7,493.3 C ≠ A ≠ B
ALT (mU/mL) 267.6 ± 226.4 129.7 ± 95.2 75.1 ± 67.9 A ≠ B ≠ C
Total bilirubin (mg/dL) 7.1 ± 9.2 4.1 ± 12.4 1.9 ± 2.2 A ≠ B ≠ C
Cirrhosis 5 31 40 A ≠ B = C
Table 2. Timing of detection and diagnostic modalities of hepatocellular carcinoma (HCC) in different groups
Group A Group B Group C
Total case no. 17 39 41
HCC total cases/males 3/3 14/10 41/29
Time of HCC detection
At enrolment 0 0 41
< 1 yr 1 8 –
1–2 yr 0 5 –
> 2 yr 2 1 –
Mean ± SD (mo) 33.0 ± 16.1 12.7 ± 8.0 –
Range (9–42) (4–25) –
HCC-free follow-up duration, 22.2 ± 16.2 (1–42) 26.7 ± 13.3 (1–47) –
mo (range)*
CT/MRI study
Before HCC detection 9 25 –
At HCC detection 3 14 39
Diagnosis of HCC
Cytology 1 9 20
Liver biopsy 1 3 6
Longitudinal imaging studies 1 2 15
AFP-L3/total AFP ratio (%)† 14.2 ± 11.4 17.0 ± 13.9 32.4 ± 24.2
*Included mortalities with short follow-up period; †p < 0.001.
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≥ 15% in both studies separated 6 to 35 months apart
(mean, 16.7 ± 11.8 months). In 2 of the 5 patients in
whom initial AFP-L3 ratio < 15%, it had become > 15%
in 5 and 28 months later (mean, 12.6 ± 9.9 months),
respectively.
A tail-like AFP antibody reactive variant was found
during lectin-affinity electrophoresis in a 72-year-old
woman with HCV antibody (Figure 4). Persistent ele-
vation of AFP around 100ng/mL was found for 2 years
before the patient was enrolled into group B. The tail-
like AFP variant protein migrated slower than AFP-L3
in lectin-affinity electrophoresis, which suggests a high
affinity with lectin. Ultrasound-guided needle aspira-
tion from the tumor showed dysplastic cells only. The
tumors were small, multifoci and slow growing initially.
The patient received repeated transhepatic arterial
chemoembolization and local pure ethanol injections.
One of the tumors had progressively enlarged to 6 cm
when she died 5 years after the first AFP-L3 study.
Discussion
Different clinical characteristics were found between
group A and B. HBV infection was the main etiology
(94%) in group A, whereas HCV infection was the main
etiology (70%) in group B. Liver cirrhosis was found in
75% of patients in group B and only 29% of patients
in group A. This difference may be associated with
different viral behaviors. HBV infection usually pres-
ents with intermittent acute exacerbation,26 whereas
HCV infection generally presents with mild persistent
inflammation.29–31
Elevated AFP-L3 ratio ≥ 17.5% was found in 
3 patients in Group A. A similar result was observed in
patients with fulminant hepatitis who received liver
transplantation.32 Investigators found that AFP-L3 level
correlated positively with weight of the removed liver.
These data suggest that AFP-L3 is produced during
regeneration and is not specific to HCC. Fortunately,
the elevated AFP level in such situations is generally
transient. We may differentiate regeneration from HCC
easily by chronologic studies. If AFP level does not drop
to normal level, further imaging and/or invasive studies
are indicated.
In group B, 13 of the 39 patients developed HCC
2 years after enrolment, suggesting that this group of
patients should be monitored closely. The sensitivity
for HCC detection with AFP-L3 was 53.8% and the
specificity was 70.0% when the AFP-L3 cutoff value
Sensitivity 0.71 
Specificity 0.71 
Cutoff 15.0%
Area under the ROC curve: 
0.738 (95% CI, 0.636–0.840)
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Table 3. AFP-L3 ratio at enrolment for prediction of hepatocellular carcinoma (HCC) and correlation with tumor size
Group HCC AFP-L3 < 15% AFP-L3 ≥ 15% Total p
A Non-HCC 11 (68.7%) 5 (31.3%) 16 NS
HCC 0 (0%) 1 (100%) 1
B Non-HCC 19 (73.1%) 7 (26.9%) 26 0.098
HCC 6 (46.2%) 7 (53.8%) 13
C HCC 10 (24.4%) 31 (75.6%) 41
Total Non-HCC 30 (71.4%) 12 (28.6%) 42 0.000
HCC 16 (29.1%) 39 (70.9%) 55
Size of HCC at 
AFP-L3 study
Undetectable HCC 6 (42.9%) 8 (57.1%) 14 0.037
< 2 cm HCC 6 (40%) 9 (60%) 15
2–5 cm HCC 3 (18.7%) 13 (81.3%) 16
> 5 cm HCC 1 (10%) 9 (90%) 10
Figure 2. The receiver operating characteristic (ROC) curve for
AFP-L3 in the total number of study patients.
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was 15%. The sensitivities of AFP-L3 from other reports
were generally around 30% to 60%, while the speci-
ficity was around 70% to 90%.9–25 Although the pres-
ent study focused on patients with persistent elevation
of AFP (group B), our results were similar to those of
other reports. In patients with persistent elevation of
AFP, the total AFP can no longer provide information
for early detection. Our data suggest that about 60%
of such patients may obtain reliable information for
prediction of HCC.
The diagnosis of HCC is difficult in the early stage,
even with histologic study. Taketa et al reported that
AFP-L3 changed from negative to positive in 4.0 ±
4.9 months before HCC was detected by imaging
study.11 In this study, 8 of the 14 patients with HCC
detected within 2 years had AFP-L3 ≥ 15% at 4 to 
24 months before the imaging-detectable HCC. One
such case is presented in Figure 1. The patient had high
and persistent elevation of AFP 2 years before a 2.5-cm
nodule in the caudate lobe was removed. The AFP-L3
ratio was 70% at 20 months before it was detected by
imaging study. In group B, AFP-L3 elevation could be
identified 12.4 months (range, 4–25 months) before
the diagnosis of HCC.
A tail-like AFP antibody-reactive protein was found
in a 72-year-old patient with HCV antibody. Persistent
elevation of AFP around 100 ng/mL was found 2 years
before she was enrolled into group B. This protein was
not associated with poor preparation of sera, because
2 lectin-affinity electrophoreses separated by 36 months
showed similar findings. The tumors were characterized
by small, multifoci and slow growing nodules. This type
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Figure 3. Hepatocellular carcinoma (HCC)-free survival analysis between patients with different AFP-L3 ratios in group A and B patients.
Patients with AFP-L3 ratio ≥ 15% of total α-fetoprotein (AFP) developed more HCC and showed a lower HCC-free survival (p = 0.072).
A B C D
Figure 4. α-Fetoprotein (AFP) tailing phenomenon in a patient
with hepatocellular carcinoma (HCC). A hepatitis C virus antibody-
positive patient was found to have elevated AFP persistently for 
2 years before the first AFP-L3 study. A faint AFP-L3 (Lane C,
arrowhead) and an additional tail (arrow) were found. Computed
tomography revealed liver cirrhosis without tumor at that time.
The second AFP-L3 study was done 3 years later. The AFP antibody-
reactive tail was still observed and migrated slower than in the
first study (Lane D, white arrow). Aspiration cytology revealed dys-
plastic cells only, but both computed tomography and angiogra-
phy studies showed multiple small hypervascular nodules in both
lobes of the liver. Repeated pure ethanol ablation and transarter-
ial chemoembolization were performed. The main tumor progres-
sively enlarged to 6 cm and the patient died of hepatic failure 
5 years after the first AFP-L3 study. Lane A is the standard loaded
with 100ng of AFP-L3. Lane B is of a patient with acute exacerbation
(AFP-L3 ratio, 10%).
of AFP-L3 should be classified into positive test for
HCC. More observations in this AFP variant are needed
to disclose its significance.
In conclusion, AFP-L3 study provides a clue in HCC
detection in patients with persistent elevation of AFP.
However, AFP-L3 could be highly elevated in patients
with severe liver damage.
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